Latest Hotspot

FDA Approves Biweekly TECVAYLI® for Refractory Multiple Myeloma

27 February 2024
3 min read

Johnson & Johnson has declared that the U.S. Food and Drug Administration granted authorization for an updated dosing regimen of TECVAYLI® (teclistamab-cqyv). Under the new protocol, the medication can be administered at a rate of 1.5 mg/kg biweekly to individuals with relapsed or refractory multiple myeloma who have secured and sustained at least a complete response for a duration no less than six months.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

TECVAYLI® (teclistamab-cqyv), a bispecific antibody, was designed to target both the BCMA present on multiple myeloma cells and CD3 found on T-cells. This unique mechanism is intended to trigger an immunological attack on the cancer cells. Authorized for public use in October 2022, TECVAYLI® is reserved for those cases of multiple myeloma that have relapsed or are resistant to treatment (RRMM) in adults, with the stipulation that patients must have previously completed a minimum of four distinct therapeutic regimens. These should comprise treatment with a class of compounds known as proteasome inhibitors, medicines with immunomodulatory properties, and therapies involving anti-CD38 monoclonal antibodies.

The U.S. FDA granted TECVAYLI® a preliminary green light based mainly on the observed rates of response in patients; this provisional approval will be subject to further assessment based on proofs of ongoing clinical benefits that emerge from subsequent studies. Since its market introduction, over 3,600 U.S. patients have started treatment with TECVAYLI®.

The clinical evidence leading to TECVAYLI®'s authorization emerged from data collected in the MajesTEC-1 trial, which encompassed both Phase 1 and Phase 2 exploratory studies. Initially, participants received a standard Phase 2 dosage, which was 1.5 mg/kg of TECVAYLI® administered via subcutaneous injection on a weekly basis. For individuals who demonstrated a durable Complete Response (CR) for at least half a year, study protocols permitted a reduction in the frequency of their injections to once every two weeks (1.5 mg/kg Q2W), continuing unless the disease advanced further or the side effects became intolerable.

In summary, TECVAYLI®, the pioneering bispecific antibody targeting BCMA and CD3, represents a significant therapeutic option for adults with heavily pre-treated RRMM, and its continued use hinges on confirming its benefits in clinical trials.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click! 

图形用户界面

描述已自动生成 According to the data provided by the Synapse Database, As of February 26, 2024, there are 31 investigational drugs for the BCMA and CD3 target, including 14 indications, 50 R&D institutions involved, with related clinical trials reaching 110, and as many as 6735 patents.

Teclistamab's approval in multiple countries and its ongoing regulatory process in China demonstrate its potential as a treatment option for patients with various hematologic malignancies. The drug's ability to target BCMA and CD3, coupled with its regulatory designations, positions it as a significant development in the field of biomedicine. Further studies and real-world evidence will be crucial in assessing the drug's long-term efficacy and safety profile.

图形用户界面, 文本, 应用程序

描述已自动生成

Exploring the Latest new anti-obesity drugs Deal by EraCal Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
3 min read
Exploring the Latest new anti-obesity drugs Deal by EraCal Therapeutics: A Guide to Rapidly Accessing Transaction Insights
27 February 2024
On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.
Read →
Polpharma Biologics' Biosimilar Matches Entyvio® in Pharmacokinetics and Dynamics Study
Latest Hotspot
3 min read
Polpharma Biologics' Biosimilar Matches Entyvio® in Pharmacokinetics and Dynamics Study
27 February 2024
The experimental biosimilar by Polpharma Biologics demonstrates similar pharmacokinetics and dynamics to the top-selling IBD medication, Entyvio®.
Read →
Unveiling Acyclovir: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Acyclovir: How to Search for it on Synapse
27 February 2024
Acyclovir, sold as ZOVIRAX, is a synthetic drug that inhibits herpes viruses, including HSV-1, HSV-2, and VZV, both in lab and living organisms.
Read →
Voyager's Gene Therapy Shows Promise in Early Alzheimer's Trial, Advances to Later Phase
Latest Hotspot
3 min read
Voyager's Gene Therapy Shows Promise in Early Alzheimer's Trial, Advances to Later Phase
27 February 2024
Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.